Skip to main content

Advertisement

SpringerLink
Log in

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

An Invited Commentary to this article was published on 04 February 2010

Abstract

Circulating tumor cell (CTC) count has been shown to be an independent predictor of progression in metastatic breast, prostate, and colorectal cancer. A cutpoint is generally used to identify favorable and unfavorable response groups. In this study, we propose an approach in which the number of CTCs is analyzed as a continuous predictor, to detect the shape of the relationship between CTCs and prognosis of metastatic breast cancer. We evaluated the association of baseline CTC with progression-free survival (PFS) and overall survival (OS) in a series of 80 patients treated for advanced breast cancer at the European Institute of Oncology, Milan. The association between CTCs and prognosis was analyzed with standard categorical survival analysis and spline regression models. At baseline, median age was 55 years; 33 patients were newly diagnosed with metastatic breast cancer (41%), while 28 (35%) and 19 (24%) were pretreated with one and two previous chemotherapy lines, respectively. After a median follow-up of 28 months, 76 disease progressions and 44 deaths were observed. Kaplan–Meier curves showed a clear association between CTCs and PFS (P-value 0.03) and OS (P-value < 0.01). Patients with no CTC at baseline had a significantly better prognosis. When analyzing the CTCs as a continuous variable, we found an increase in risk with increasing number of CTCs, for both PFS and OS. The increase rate lessened after approximately 5 CTCs. CTCs represent a robust prognostic factor in the metastatic breast cancer setting. A nonlinear increase in risk of both progression and death with increasing number of CTCs was observed, with a lessening increase after approximately 5 CTCs. If distinct prognostic groups are to be identified, women with no CTC could plausibly represent a distinct favorable one.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ries LA, MP Eisner, CL Kosary et al Seer cancer statistics review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/

  2. American Cancer Society (2008) Cancer facts and figures, 2008. American Cancer Society, Oakland

  3. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430

    Article  PubMed  Google Scholar 

  4. Nole F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT (2008) Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 19:891–897

    Article  CAS  PubMed  Google Scholar 

  5. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218–4224

    Article  CAS  PubMed  Google Scholar 

  6. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF (2006) Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403–6409

    Article  CAS  PubMed  Google Scholar 

  7. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309

    Article  PubMed  CAS  Google Scholar 

  8. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G (2009) Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10:233–239

    Article  CAS  PubMed  Google Scholar 

  9. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:2023–2029

    Article  CAS  PubMed  Google Scholar 

  10. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058

    Article  CAS  PubMed  Google Scholar 

  11. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20(7):1223–1229

    Article  CAS  PubMed  Google Scholar 

  12. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221

    Article  PubMed  Google Scholar 

  13. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791

    Article  CAS  PubMed  Google Scholar 

  14. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M (2009) Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27(20):3303–3311

    Article  PubMed  Google Scholar 

  15. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25:127–141

    Article  PubMed  Google Scholar 

  16. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829–835

    Article  CAS  PubMed  Google Scholar 

  17. Austin PC, Brunner LJ (2004) Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med 23:1159–1178

    Article  PubMed  Google Scholar 

  18. Faraggi D, Simon R (1996) A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 15:2203–2213

    Article  CAS  PubMed  Google Scholar 

  19. Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561

    Article  CAS  PubMed  Google Scholar 

  20. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904

    Article  PubMed  Google Scholar 

  21. MacCallum RC, Zhang S, Preacher KJ, Rucker DD (2002) On the practice of dichotomization of quantitative variables. Psychol Methods 7:19–40

    Article  PubMed  Google Scholar 

  22. Leeflang MM, Moons KG, Reitsma JB, Zwinderman AH (2008) Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem 54:729–737

    Article  CAS  PubMed  Google Scholar 

  23. Greenland S (1995) Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 6:450–454

    Article  CAS  PubMed  Google Scholar 

  24. Royston P (2000) A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19:1831–1847

    Article  CAS  PubMed  Google Scholar 

  25. Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:356–365

    Article  CAS  PubMed  Google Scholar 

  26. Royston P, Reitz M, Atzpodien J (2006) An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer 94:1785–1788

    Article  CAS  PubMed  Google Scholar 

  27. Sauerbrei W, Royston P, Binder H (2007) Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26:5512–5528

    Article  PubMed  Google Scholar 

  28. Bagnardi V, Zambon A, Quatto P, Corrao G (2004) Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 159:1077–1086

    Article  PubMed  Google Scholar 

  29. Tibbe AG, Miller MC, Terstappen LW (2007) Statistical considerations for enumeration of circulating tumor cells. Cytometry A 71:154–162

    PubMed  Google Scholar 

  30. d’Onofrio A (2009) Fractal growth of tumors and other cellular populations: linking the mechanistic to the phenomenological modeling and vice versa. Chaos Solitons Fractals 41:875–880

    Article  Google Scholar 

  31. Wheldon TE (1988) Mathematical model in cancer research. A. Hilger, Bristol

Download references

Author information

Authors and Affiliations

  1. Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

    Edoardo Botteri, Vincenzo Bagnardi & Nicole Rotmensz

  2. Unit of Laboratory Medicine, European Institute of Oncology, Milan, Italy

    Maria Teresa Sandri, Laura Zorzino, Maria Cristina Cassatella & Michela Salvatici

  3. Department of Statistics, University of Milan-Bicocca, Milan, Italy

    Vincenzo Bagnardi

  4. Division of Medical Oncology, European Institute of Oncology, Milan, Italy

    Elisabetta Munzone, Angela Esposito, Giuseppe Curigliano, Elena Verri, Laura Adamoli, Aron Goldhirsch & Franco Nolè

  5. Division of Pathology, European Institute of Oncology, Milan, Italy

    Chiara Casadio

Authors
  1. Edoardo Botteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Teresa Sandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincenzo Bagnardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabetta Munzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Zorzino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicole Rotmensz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chiara Casadio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Cristina Cassatella
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Angela Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giuseppe Curigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michela Salvatici
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Elena Verri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Laura Adamoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Aron Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Franco Nolè
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franco Nolè.

Additional information

An invited commentary to this article can be found at doi:10.1007/s10549-010-0762-x.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Botteri, E., Sandri, M.T., Bagnardi, V. et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122, 211–217 (2010). https://doi.org/10.1007/s10549-009-0668-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0668-7

Keywords

Search

Navigation